Ovarian cancer accounts for more deaths than all other gynecological cancers combined. To identify common low-penetrance ovarian cancer susceptibility genes, we conducted a genome-wide association study of 507,094 SNPs in 1,768 individuals with ovarian cancer (cases) and 2,354 controls, with follow up of 21,955 SNPs in 4,162 cases and 4,810 controls, leading to the identification of a confirmed susceptibility locus at 9p22 (in BNC2) 1 . Here, we report on nine additional candidate loci (defined as having P ≤ 10 −4 ) identified after stratifying cases by histology, which we genotyped in an additional 4,353 cases and 6,021 controls. We confirmed two new susceptibility loci with P ≤ 5 × 10 −8 (8q24, P = 8.0 × 10 −15 and 2q31, P = 3.8 × 10 −14 ) and identified two additional loci that approached genome-wide significance (3q25, P = 7.1 × 10 −8 and 17q21, P = 1.4 × 10 −7 ). The associations of these loci with serous ovarian cancer were generally stronger than with other cancer subtypes. Analysis of HOXD1, MYC, TIPARP and SKAP1 at these loci and of BNC2 at 9p22 supports a functional role for these genes in ovarian cancer development.
Invasive epithelial ovarian cancer is a rare but often lethal disease. Individuals with a family history of ovarian cancer have an approximately twofold increased risk, even after accounting for mutations in known highly penetrant susceptibility genes, suggesting that other risk alleles await identification. Genome-wide association studies (GWAS) have identified common genetic variants influencing the risk for a range of cancers, including our recent identification of low-risk ovarian cancer alleles at 9p22.2 (ref. 1) . The most significant association identified in our previous study conferred a 20% reduction in risk with each copy of the minor allele; this association was stronger for the serous subtype of ovarian cancer, suggesting that disease heterogeneity may have reduced the power of our GWAS 1 . To identify further susceptibility alleles, we followed up additional candidate loci from that study after stratifying cases by histological subtype.
Our GWAS was performed on women of European ancestry diagnosed with the major histological subtypes of invasive epithelial ovarian cancer: serous, mucinous, endometrioid and clear cell ( Table 1 and Supplementary Table 1 ). Phase 1 included 1,768 cases and 2,354 controls from the UK who were genotyped using the Illumina Infinium 610K and 550K arrays, respectively. Data were available for 507,094 genotyped SNPs and 1,549,784 imputed SNPs from HapMap. The top ranked 21,955 SNPs, selected based on analysis of all subtypes combined, were genotyped in an additional 4,162 cases and 4,810 controls in phase 2, leading to the identification of a compelling association near BNC2 (encoding basonuclin 2) at 9p22.2 (rs3814113, P = 5.4 × 10 −22 , serous subtype) 1 . Quantile-quantile plots of the distribution of test statistics generated to compare genotype frequencies in cases versus controls in the stage 1 and stage 2 data suggested there was little evidence of any general inflation of the test statistics (estimated inflation factor λ 1,000 = 1.026 and λ 1,000 =1.0086, respectively, based on the bottom 90% of the distribution) 1 .
In the current study, combined phase 1 and phase 2 data from our previous GWAS were re-analyzed overall and also after restricting the data to only cases with the serous subtype. This revealed nine loci with P ≤ 10 −4 in all subtypes (at 1p31, 1p36, 2q31, 11p14 and 17q21) and/or in the serous subtype only (at 2p22, 3q25, 7p21 and 8q24). Thirty SNPs from these loci were genotyped in an additional 4,353 cases and 6,021 controls in phase 3; therefore, data were available for a combined analysis of 10,283 cases (including 5,841 serous cases) and 13,185 controls. In addition, results on an independent 194 cases and 40,933 controls were incorporated using meta-analyses. There was little additional evidence of association for five loci in both the phase 3 and the combined data, although the trends in association were in the same direction for some SNPs (Supplementary Tables 2  and 3) . For SNPs at two loci (2q31 and 8q24), there was strong support for associations in the phase 3 data alone (P < 0.001) and in the combined analyses of all cases or serous cases only (P ≤ 5 × 10 −8 ). At two other loci, 3q25 and 17q21, there was good evidence for association in the combined analysis of serous cases, but these associations did not reach genome wide significance (P = 7.1 × 10 −8 and P = 1.4 × 10 −7 , respectively). No heterogeneity across studies was observed (P > 0.05; Table 2 , Fig. 1 and Supplementary Fig. 1 ).
At the 8q24 locus, the minor allele of rs10088218 was associated with a decreased risk of ovarian cancer ( Table 2) , with the association being more significant for the serous subtype (odds ratio (OR) = 0.76, 95% CI 0.70-0.81, P = 8.0 × 10 −15 ); the additional 8q24 SNPs rs1516982 (r 2 = 0.46) and rs10098821 (r 2 = 0.80) also had highly significant associations (Supplementary Table 2 ). The minor allele of rs2072590 at 2q31 was associated with an increased risk of ovarian cancer, which was highly significant for the serous subtype (OR = 1.20, 95% CI 1.14-1.25, P = 3.8 × 10 −14 ) but also showed significant associations for other subtypes; more significant results were also seen for the serous subtype for minor alleles of rs2665390 at 3q25 (OR = 1.24, 95% CI 1.15-1.34, P = 7.1 × 10 −8 ) and rs9303542 at 17q21 (OR = 1.14, 95% CI 1.09-1.20, P = 1.4 × 10 −7 ).
We observed significant heterogeneity for the associations at the 8q24 and 2q31 loci when cases were stratified into the four histological subtypes (P = 2.9 × 10 −4 for rs2072590 and P = 1.1 × 10 −7 for rs10088218) ( Table 2) . For both loci, the trends in association for the endometrioid and mucinous subtypes were in the same direction as the serous subtype, but there was no evidence of association at either locus in the clear cell subtype. To a lesser degree, a difference in risk by subtype was also observed at 3q25 (P = 0.02 for rs2665390). We also examined SNP associations by age and family history of ovarian cancer in first-degree relatives. No differences in risk were observed by age (Supplementary Table 4 ) and, among the four new loci, no interactions by family history were observed (Supplementary Table 5) .
We also tested the most significant riskassociated SNPs at 8q24, 2q31, 3q25 and 17q21 for association with overall survival after a diagnosis of ovarian cancer in all and in serous only case subgroups. For the latter group, we also performed an analysis adjusting for tumor stage and grade. We found borderline evidence for an association with survival at 17q21 in all cases (hazard ratio (HR) = 1.06, 95% CI 1.00-1.13, P = 0.04) and also in only serous cases (HR = 1.08, 95% CI 1.00-1.16, P = 0.04). This effect was not greatly attenuated when adjusting for stage and grade among only serous cases (HR = 1.06, 95% CI 0.97-1.15, P = 0.15). There was no evidence of association with survival at 8q24, 2q31 or 3q25. OR, per-allele odds ratio; 95% CI, confidence interval. Phase 1 and phase 2 data were adjusted for study site and the first principal component. Note that rs2665390 and rs10088218 were selected for phase 3 based on combined results across phases in serous cases (data not shown). Phase 3 data were adjusted for study site. ICE data were included for the combined analysis of rs2072590, rs2665390 and rs10088218 using meta-analytic techniques. No consistent patterns of heterogeneity were found when including ICE data and so only fixed effects meta-analysis results are presented. P het represents the heterogeneity test across all studies for the combined analyses of all phases and, for subtype analyses, across subtypes excluding the ICE study. Endometrioid, mucinous and clear cell analyses are not adjusted for study. Bold indicates association at P < 10 -6 and heterogeneity at P < 0.05.
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We used Pupasuite (see URLs) for in silico analyses of risk-associated SNPs and strongly correlated SNPs (r 2 >0.80) in the four loci, but we failed to find compelling evidence for any functional role (Supplementary Table 6 ). Genotyping of additional SNPs identified from HapMap and the 1000 Genomes Project (see URLs) is required to fine map these loci to identify both causal variants and target genes. Even so, known genomic architecture may provide some insight into the functional mechanisms underlying ovarian cancer susceptibility. For example, common variants at 8q24 have previously been shown to confer susceptibility to multiple cancer phenotypes, including prostate, colorectal, breast and bladder cancers [2] [3] [4] [5] [6] [7] , and previous functional studies have suggested that common variants may be associated with transcriptional regulation of MYC 8, 9 . Most risk associations at 8q24 are located 5′ of MYC, but the three most significant SNPs for ovarian cancer lie >700 kb 3′ of MYC in an apparent gene desert, suggesting either that MYC is not the target gene for ovarian cancer or that variants in this region are also capable of distant regulation of MYC (Fig. 1a) .
rs2665390 at 3q25 is intronic to TIPARP; there are no other candidate genes within 200 kb of this SNP (Fig. 1b) . TIPARP is a poly (ADP-ribose) polymerase (PARP) 10 and is a particularly intriguing candidate gene for ovarian cancer for two reasons. First, recent reports show that BRCA1-BRCA2-deficient cells survive by using PARP1 as an alternative DNA repair mechanism 11 . This has led to the development of a new therapy based on synthetic inhibition of PARP1 for breast and ovarian cancer patients carrying BRCA1 or BRCA2 mutations 12 . Second, TIPARP expression is induced by dioxin 13 , raising the possibility that this environmental contaminant may influence ovarian cancer risk among susceptible women.
The 2q31 locus contains a family of homeobox (HOX) genes involved in regulating embryogenesis and organogenesis (Fig. 1c) . Altered expression of HOX genes has been reported in many cancers 14, 15 . The ovarian cancer risk-associated SNP rs2072590 lies in noncoding DNA downstream of HOXD3 and upstream of HOXD1, and it tags SNPs in the HOXD3 3′ untranslated region. Both genes have been implicated in neoplastic development 16, 17 .
Finally, associated and correlated SNPs at 17q21 are intronic to SKAP1, which has strong homology to the SRC oncogene at the C-terminal end (Fig. 1d) . SKAP1 regulates mitotic progression, specifically at the transition of metaphase to anaphase 18 . In T cells, constitutive expression of SKAP1 suppresses activation of RAS and RAF1, both of which have been implicated in the early stage development of ovarian cancer 19 .
We evaluated risk-associated SNPs and candidate genes from these four previously unidentified loci, as well as from BNC2 (ref. l e t t e r s and SKAP1 (17q21). We found no evidence of genotype-associated gene expression in an analysis of 48 normal primary human ovarian surface epithelial (POE) cell cultures (Supplementary Table 7) , although our study power was limited due to the relatively small number of subjects. We also compared the expression of each of the five candidate genes between 48 POE and 24 ovarian cancer cell lines and found highly significant differences in gene expression between normal and cancer cells for BNC2, TIPARP, HOXD1 and SKAP1 (Fig. 2 and Supplementary Fig. 2 ). These data suggest that BNC2 and TIPARP have a loss-of-function role and that HOXD1 and SKAP1 have a gain-of-function role in ovarian cancer development.
Gene expression was also examined in an in vitro model of ovarian cancer initiation and progression established through oncogenic expression of MYC and mutant KRAS G12V in POE cells (Fig. 2 and  Supplementary Table 8) . We found that BNC2 and TIPARP expression decreases, and SKAP1 expression increases, with neoplastic development, consistent with the expression of these genes in POE cells compared to ovarian cancer cells. We also investigated gene expression for 216 primary serous ovarian cancer samples analyzed by The Cancer Genome Atlas Project (see URLs). These data support frequent loss of BNC2 and TIPARP expression and gain of HOXD1 expression in ovarian cancer development (Supplementary Fig. 3 ).
In summary, we report two confirmed previously unidentified common low-penetrance ovarian cancer susceptibility loci and a further two candidate susceptibility loci, adding to a growing list of susceptibility loci that includes BNC2 and the 19p13 locus presented in an accompanying report 20 . All six susceptibility loci suggest possible functional relevance of candidate genes that could plausibly be involved in ovarian cancer development and aid in our understanding of disease etiology. Notably, these data also suggest that common germline variation influences the clinico-pathological development of disease, as previously reported for the highly penetrant germline variants in BRCA1 and BRCA2 (ref.
21).
URLs. PupaSuite, http://pupasuite.bioinfo.cipf.es/; 1000 Genomes Project, http://www.1000genomes.org/page.php; The Cancer Genome Atlas Project, http://cancergenome.nih.gov/; MACH, http://www. sph.umich.edu/csg/abecasis/MACH/; http://ccr.coriell.org/Sections/ Search/Panel_Detail.aspx?PgId=202&Ref=HAPMAPPT01/.
MeTHOdS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
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ONLINe MeTHOdS Phase 1 and 2. As described previously 1 , phase 1 self-reported white European participants were from four collections of invasive epithelial ovarian cancer cases and two collections of controls [22] [23] [24] (Supplementary Table 1) . Logistic regression and linear trend tests examined SNP associations (including imputed genotypes) using imputed genotype weights and ethnicityrelated principal components. Phase 2 SNPs were selected based on phase 1 ranked test statistics (all cases and serous cases) weighted by imputation status and accuracy (r 2 ) 25 , and design score, and all participants were of European ancestry and came from 12 studies. Logistic regression adjusted for a HapMap-based ancestry score 26 and an ancestry-informative marker-based principal component.
Phase 3.
Sixteen studies contributed invasive epithelial ovarian cancer cases and controls of European ancestry (Supplementary Table 1 ). Nine loci (comprising 30 SNPs; Supplementary Table 9) were selected based on test statistic rankings from combined phase 1 and phase 2 analyses (P < 10 −5 in all or serous cases). Eleven studies used TaqMan (two SNPs) and Sequenom MassARRAY (the remaining SNPs). Data from four studies were available from a genome-wide scan using the same Illumina Infinium 610K array that was used in phase 1, excluding samples with call rate <95%, >1% discordance, <80% European ancestry or ambiguous gender. For one study, Illumina Infinium 317K data were used, with imputation based on HapMap CEU data following 100 iterations in MACH version 1.0.16 (see URLs), excluding SNPs with r 2 < 0.30. For one study, cases and ~2,900 controls were genotyped on a Centaurus (Nanogen) platform (excluding SNPs with >1.5% HapMap mismatch), and additional control data used the Illumina Infinium 317K and HumanCNV370-Duo BeadArrays; per-SNP call rate was >97% and concordance was >98.5%. Logistic regression modeled the number of observed or imputed minor alleles, and no confounding by age was observed. Combined analyses were adjusted for study and heterogeneity was tested with Cochran's Q statistic and I 2 values. Effect modification and differences in risk by subtype were tested with interaction terms and polytomous regression, respectively. Summary-level data were available for the ICE study; thus meta-analytic techniques fitted fixed and random effects 27, 28 .
Genotyping quality control measures. The Ovarian Cancer Association Consortium (OCAC) has established robust genotyping quality control guidelines to ensure accurate genotyping, particularly across multiple studies. Data included must pass the following quality control criteria: (i) > 3% duplicate samples included in each study; (ii) samples from cases and controls must be mixed on 384 well plates; (iii) samples that consistently fail (for example, for >20% of all SNPs) are removed; (iv) genotype data for a SNP are removed if the call rates are >90% for each individual 384-well plate, but if >25% plates from any site are excluded for this reason, then all the data from that site are excluded; (v) the overall call rate for a SNP for each study must be >95%, which is calculated after ineligible samples and plates are excluded; (vi) genotyping concordance rates for the duplicates must be >98%; (vii) Hardy Weinberg Equilibrium (HWE) in white European controls must be P ≥ 0.005. If the HWE P is between 0.05 and 0.005, the genotyping clustering quality is reviewed by members of the OCAC genotyping committee (P.D.P.P., G.C.-T., S.J.R. and H.S.) before inclusion. In addition, as part of overall quality control measures, genotyping consistency across labs is evaluated by genotyping a panel of HapMap CEU trios including 90 individual DNA samples, five duplicate samples and one negative control (see URLs). Genotyping concordance between centers must be >98% in order for the genotype data to be included. Genotyping quality control measures for phase 1 and phase 2 of the GWAS have been described previously 1 .
Genotyping quality control in the current study. In phase 1, 507,094 out of 540,573 SNPs (94%) passed quality control filters. In both phase 1 and phase 2, duplicate concordance rates were 99.9%. For phase 3, the data from the five studies using GWAS data met the following overall quality control criteria: (i) self-reported Caucasian and greater than 80% European ancestry; (ii) sample call rate ≥95%; (iii) SNP call rate ≥95%; (iv) 100% concordance of duplicates (in 81 replicate pairs); and (v) HWE P ≥ 10 −4 for each SNP. The Sequenom and TaqMan data met the OCAC criteria described above.
The results from phase 3 genotype quality control procedures for each of the 30 SNPs are summarized in Supplementary Table 10. 
